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Abstract
Background: Considerable efforts have been made to characterize the pathways regulating the extracellular levels of the
endocannabinoid anandamide. However, none of such pathways has been so argued as the existence of a carrier-mediated
transport of anandamide across the membrane. Apart from the lack of molecular evidence for such a carrier, the main
reasons of this controversy lie in the methodologies currently used to study anandamide cellular uptake. Furthermore, the
main evidence in favor of the existence of an ‘‘anandamide transporter’’ relies on synthetic inhibitors of this process, the
selectivity of which has been questioned.
Methodology/Principal Findings: We used the cytosolic binding site for anandamide on TRPV1 channels as a biosensor to
detect anandamide entry into cells, and exploited nanotechnologies to study anandamide membrane transport into intact
TRPV1-overexpressing HEK-293 cells. Both fluorescence and digital holographic (DH) quantitative phase microscopy were
used to study TRPV1 activation. Poly-e-caprolactone nanoparticles (PCL-NPs) were used to incorporate anandamide, which
could thus enter the cell and activate TRPV1 channels bypassing any possible specific protein(s) involved in the uptake
process. We reasoned that in the absence of such protein(s), pharmacological tools previously shown to inhibit the
‘‘anandamide transporter’’ would affect in the same way the uptake of anandamide and PCL-NP-anandamide, and hence the
activation of TRPV1. However, when masked into PCL-NPs, anandamide cellular uptake became much less sensitive to these
agents, although it maintained the same pharmacokinetics and pharmacodynamics as that of ‘‘free’’ anandamide.
Conclusions: We found here that several agents previously reported to inhibit anandamide cellular uptake lose their efficacy
when anandamide is prevented from interacting directly with plasma membrane proteins, thus arguing in favor of the
specificity of such agents for the putative ‘‘anandamide transporter’’, and of the existence of such mechanism.
Citation: Ligresti A, De Petrocellis L, Herna ´nP e ´rez de la Ossa D, Aberturas R, Cristino L, et al. (2010) Exploiting Nanotechnologies and TRPV1 Channels to
Investigate the Putative Anandamide Membrane Transporter. PLoS ONE 5(4): e10239. doi:10.1371/journal.pone.0010239
Editor: Olivier Jacques Manzoni, INSERM U862, France
Received February 17, 2010; Accepted March 29, 2010; Published April 22, 2010
Copyright:  2010 Ligresti et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was partly funded by the Consiglio Nazionale delle Ricerche. The funder had no role in study design, data collection and analysis, decision to
publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: vdimarzo@icmib.na.cnr.it
. These authors contributed equally to this work.
Introduction
N-arachidonoyl-ethanolamine (anandamide, AEA), the first
endocannabinoid to be discovered [1] exerts its actions at
cannabinoid receptors ‘‘on demand’’ and acts as an autocrine/
paracrine mediator. The extent and duration of these actions is
determined by AEA extracellular concentration, which, in turn, is
controlled by the rate of AEA synthesis and degradation. Since
AEA metabolic pathways consist of biosynthetic and hydrolytic
enzymes that are intracellularly located, an efficient transport
system allowing for the rapid trafficking of AEA through these
topographically separated sites was proposed. According to this
idea, the uptake of extracellular AEA by the cell might occur as
follows: (a) adsorption to the plasma membrane, (b) transmem-
brane movement, (c) desorption from the plasma membrane, and
(d) intracellular trafficking, accumulation, and hydrolysis. Howev-
er, it is still being argued as to whether the first two steps, i.e. the
transport across the membrane, occur via a protein-dependent or
independent mechanism. The lack of molecular evidence for the
presence of an AEA ‘‘membrane transporter’’ has generated a
heated debate on this subject. Although this putative ‘‘carrier’’ has
yet to be cloned, indirect biochemical and pharmacological
evidence suggests its existence. It has been extensively reported
that AEA diffusion through the cell membrane occurs via a
saturable, temperature-dependent and selective mechanism [2–6].
Furthermore, selective inhibitors of AEA uptake, capable of
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pharmacology distinct from that of inhibitors of other AEA
inactivation processes, have been developed [4,7–11]. However,
the temperature-dependency and saturability typical of AEA
uptake could be explained also without the presence of a specific
transporter [12,13]. Moreover, the selectivity of some of the
transport inhibitors used so far has recently been questioned ([14],
but see also [15]). Furthermore, a contentious has been generated
by the different procedures employed for studying the ‘‘AEA
transporter’’ [16,17]. In fact, not only AEA uptake assays might
provide different results depending on the experimental conditions
[18], but also other factors (i.e. intracellular metabolism, binding
to cellular protein or to plastic ware in the absence of albumin)
may complicate the measurement of the passage of AEA through
the plasma membrane [13].
To help solving this conundrum, here we first decided to study
the features of AEA uptake by using an intracellular ‘‘biosensor’’ as a
measure of AEA entry into cells, i.e. the activation of the transient
receptor potential vanilloid type-1 (TRPV1) channel, which
possesses a unique intracellular binding site for AEA in its TM3–
TM4 region [19], and responds to the endocannabinoid by gating
Ca
2+ entry into the cell. We performed our experiments in HEK-
293 cells overexpressing the recombinant TRPV1 protein (TRPV1-
HEK-293 cells), which also possess low levels of expression of the
AEA-degrading enzyme, fatty acid amide hydrolase (FAAH)
[20,21]. The activity of TRPV1 was measured both by a
conventional fluorescence method to measure intracellular Ca
2+
and digital holographic (DH) quantitative phase microscopy, which
detects cell surface topology perturbations that follow to Ca
2+ entry.
Furthermore, we decided to study the uptake of AEA incorporated
into nanoparticles, which are used to facilitate drug delivery to
intracellular targets and by-pass any specific and functional
interaction with membrane proteins. We reasoned that, if no
membrane transporter exists for AEA, one should see no difference
in the sensitivity of its uptake to previously reported inhibitors of this
process, whether the compound is left free to interact with proteins,
or ‘‘disguised’’ into nanoparticles. We expected that, in the absence
of a membrane transporter, the pharmacology of AEA uptake by
TRPV1-HEK-293 cells would be undistinguishable from that of the
uptake of AEA incorporated into poly-e-caprolactone nanoparticles
(PCL-NPs). If this was not the case, this would negate the lack of
selectivity of the inhibitors used and hence represent novel evidence
for the existence of an AEA transporter.
Results
Validation of TRPV1 as a biosensor for the study of AEA
cellular uptake
In order to validate the use of TRPV1 activation as a biosensor
of AEA cellular uptake, irrespective of the mechanism of this latter
process, we compared the effect of several pharmacological tools
previously shown to interfere with AEA cellular uptake on AEA-
and capsaicin-induced elevation of intracellular Ca
2+ as a measure
of TRPV1 activity in TRPV1-HEK-293 cells. As previously shown,
AEA induced a dose-dependent increase of intracellular Ca
2+
([Ca
2+]i), measured with Fluo-4. The effect of AEA (1 mM), apart
from the selective inhibitor of TRPV1 channels, 59-iodo-resinifer-
atoxin (I-RTX), was significantly reduced by: 1) bovine serum
albumin (BSA), which sequesters AEA from the extracellular
medium; 2) OMDM-1 (a specific inhibitor of AEA cellular uptake
with no effect on AEA enzymatic hydrolysis [9,22]; 3) methyl-b-
cyclodextrin (MbCD) (which interferes with AEA cellular uptake by
inhibiting the formation of membrane lipid rafts [23,24] and 4)
oleic acid (OA) and the specific FABP4 inhibitor [(29-(5-Ethyl-3,4-
diphenyl-1H-pyrazol-1-yl)(1,19-biphenyl)-3-yl)oxy]-acetic acid, two
inhibitors of the intracellular trafficking of AEA via fatty acid
binding proteins [25,26] (Fig. 1A). By contrast, the effect of
Figure 1. TRPV1 activation as biosensor for the study of
anandamide (AEA) cellular uptake. (A) AEA-induced elevation of
[Ca
2+]i in intact HEK-293 cells over-expressing the human recombinant
TRPV1 receptor was significantly reduced by I-RTX (a selective TRPV1
antagonist) as well by a series of compounds that selectively affect
membrane transport processes such as bovine serum albumin) BSA
(which sequesters AEA from the extracellular medium); OMDM-1 (a
specific inhibitor of AEA cellular uptake with no effect on AEA enzymatic
hydrolysis); MbCD (which interferes with AEA cellular uptake by inhibiting
the formation of membrane lipid rafts) and oleic acid (OA) and a specific
fatty acid binding protein 4-blocker (FABP4 inh) (two inhibitors of the
intracellular trafficking of AEA via fatty acid binding proteins). ***p,0.001
compared to AEA+ vehicle (n=3–5).(B) Capsaicin (CPS)-induced elevation
of [Ca
2+]i in intact HEK-293 cells over-expressing human TRPV1 receptors
was significantly antagonized by I-RTX, but was insensitive to all other
compounds that selectively affect membrane transport processes (BSA,
OMDM1, MbCD, OA, FABP4 inhib). ***p,0.001 compared to CPS+ vehicle
(n=3–5). Data are expressed as percent of the maximal response
observed with either AEA (1 mM, 72.061% of the effect of ionomycin,
4 mM, see also Fig. 6A) or CPS (7668% of ionomycin, 4 mM). Each bar
indicates means 6 sem of at least 3 independent experiments.
doi:10.1371/journal.pone.0010239.g001
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does not compete with AEA for its uptake, and clearly crosses the
plasma membrane through a process different from that involved in
AEA transport [7,20], was antagonized by I-RTX, but was mostly
insensitive to other compounds that selectively affect only
membrane transport processes (Fig. 1B). These findings indicate
that elevation of [Ca
2+]i in intact TRPV1-HEK-293 cells can be
used as a biosensor for AEA cellular uptake in these cells.
Importantly, over-expression of human recombinant TRPV1 in
HEK-293 cells was not accompanied by any significant change in
the expression of cannabinoid CB1 or CB2 receptors or of FAAH,
nor of endogenous AEA levels, as compared to wild-type HEK-293
cells. Furthermore, wild-type HEK-293 cells did not respond to
either AEA or capsaicin up to concentrations of 10 mM [20,21].
We further validated TRPV1 as a biosensor for AEA uptake by
using digital holographic (DH) quantitative phase microscopy
instead of [Ca
2+]i measurements. This technique is able to record
and then reproduce the light-wavefront scattered from an object,
thus allowing the formation of an image of the object itself. This is
obtained by recording the ‘‘hologram’’ generated by the optical
interference between the light coming from the object and a
reference light beam. In particular, DH microscopy was applied to
study the effect of AEA on TRPV1-HEK-293 cell surface
topology, which consisted in the rapid (200–300 s) induction of
membrane extrusions in a TRPV1- and extracellular Ca
2+-
dependent manner (Fig. 2, Video S1, Video S2). This effect of
AEA was dramatically delayed by the presence in the culture
medium of fetal bovine serum (10%) or by OMDM-1 (Fig. 3A).
The Ca
2+ ionophore ionomycin (induction time 200–400 s), but
not the endoplasmic reticulum Ca
2+-ATPase inhibitor, thapsigar-
gin, which mobilizes intracellular Ca
2+, also exerted a very similar
effect. Capsaicin was capable of inducing a very similar TRPV1-
and extracellular Ca
2+-dependent effect (induction time 100–
200 s), although in a way entirely insensitive to BSA and OMDM-
1 (Fig. 3B). AEA and capsaicin also caused intracellular light-phase
variations, which at present cannot be related to any biochemical
effect. A large amount of the collected data will be analyzed in
detail in a future paper.
The encapsulation of AEA into PCL-NPs allows its cellular
internalization and cytosolic release
PCL-NPs were selected for their biocompatibility, lipophilicity,
cost-effectiveness and capability to support passive uptake
processes, as compared with other polyesters, and were prepared
by the nanoprecipitation technique. AEA loading was determined
to be 400–500 mg/ml. More than 95% of the drug initially added
was entrapped within the polymeric matrix (96.0561.77%).
Particle size was highly reproducible and showed a mean volume
(mv) size around 80 nm (83.5265.3) and 20 nm (21.3865.7)
population width. These parameters were not dependent on the
presence of drug (‘‘empty’’ NP mv was 78.963.82 nm and
population width 22.9565.87 nm). Immediate release tests
demonstrated that AEA possesses a strong interaction with the
polymeric matrix. More than 90% of the drug initially entrapped
remains associated to the carrier with a 50% dilution of NP. If
diluted to 90% only a small fraction is released (15%). When the
dilution is as high as 99%, AEA concentrations in the supernatant
(1.8360.22mg/ml) is comparable to the reported solubility
coefficient for THC in aqueous media (2.8 mg/ml) [27] and this
is the dilution at which significant drug release takes place,
suggesting that solubility in the external medium is a key factor.
Figure 2. Use of digital holographic (DH) quantitative phase microscopy for the study of AEA uptake. Representative phase images for
the effects of anandamide (AEA, 1 mM) in non-transfected HEK-293 cells, and of AEA (1 mM), capsaicin (CPS, 0.5 mM) and PCL-NP-AEA (1 mM) on
TRPV1-HEK-293 cell surface topology as observed with digital holographic (DH) quantitative phase microscopy. Apparent membrane extrusions,
observed in a TRPV1- and extracellular Ca
2+-dependent way (see Fig. 3), are shown at ,200 sec after addition of the drugs (lower panels), whereas
the cell surface topology of the same cells is also shown at time 0, prior to addition of the substances (upper panels). See also Videos S1 and S3.
doi:10.1371/journal.pone.0010239.g002
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is not so strong as to prevent AEA release into an aqueous solvent
such as the cytosol. However, despite the fact that further dilutions
decrease the supernatant concentrations below its solubility
coefficient, significant amounts of AEA are still retained by the
NP (up to 47%), indicating that a large part of the drug is more
stably associated with the NP in the absence of a stronger
‘‘binder’’. Indeed, the effect of time on drug release at high
dilution (99%) showed a two phase profile, with a rapid (but still
detectable only after 5 min) release of about 53% of the AEA
initially entrapped. Afterwards, the remaining amount of drug
remains associated to the polymeric carrier for at least 24 h
(Fig. 4A). We also monitored AEA entrapment into PCL-NPs at
the final dilution (1mM, 1:1000) of the stock suspension and with
the same buffer used in the uptake/[Ca
2+]i experiments, by
centrifuging the suspension at 15,0006g within 2 min from the
dilution, and by quantifying AEA release into the supernatant by
LC-MS, as previously described [10,28]. This experiment showed
that, under these conditions, most of the AEA was retained into
the polymeric matrix, since we could detect in the supernatant
only 20.262.1% (mean6SD, n=3) of the total AEA incorporated
into the PCL-NPs.
In order to confirm that PCL-NP’s rapidly enter TRPV1-HEK-
293 cells, we used a microscopy technique, by incubating TRPV1-
HEK-293 cells with PCL-NPs encapsulating Rhodamine-123
(PCL-NP-Rho) instead of AEA, and by detecting cytoplasmatic
rhodamine under fluorescence microscopy. Rhodamine-123 was
efficiently loaded on the PCL-NP approaching 70% of the dye
initially added. Particle size was highly reproducible and showed a
mean volume (mv) size around 70 nm (76.35614.35) and 25 nm
(26.55613.78) population width. Immediate release tests evi-
denced that no rhodamine was released up to 75% NP dilution.
PCL-NP-Rho was rapidly and efficiently internalized by cells, as
demonstrated by the appearance of cytoplasmic rhodamine within
1 minute (Fig. 4B, C). No effect on cell fluorescence was seen with
‘‘empty’’ PCL-NPs (Fig. 4D).
The uptake of PCL-NP-AEA has similar
pharmacodynamics and pharmacokinetics as ‘‘free’’ AEA
uptake but is significantly less sensitive to various
inhibitors
Like ‘‘free’’ AEA, PCL-NP-AEA induced a rapid elevation of
[Ca
2+]i in TRPV1-HEK-293 cells (Fig. 5A,B). Since PCL-NP-
AEA needs to be kept at room temperature (25uC) in order to
allow stability of nanoparticles, we monitored for 10 days its
efficacy as enhancer of [Ca
2+]i in these cells. The effect of 100 nM
PCL-NP-AEA was checked daily and no significant change in
efficacy was observed for up to 10 days, unlike what observed with
100 nM free AEA, the effect of which was reduced at day 10 by
50.564.3% (mean6SD, n=3). Importantly, almost no effect on
cell fluorescence was seen with ‘‘empty’’ PCL-NPs (Fig. 5C).
The effect of PCL-NP-AEA on [Ca
2+]i in TRPV1-HEK-293
cells was dose–dependent and TRPV1-mediated because it was
abolished by I-RTX (Fig. 6A). It exhibited nearly identical kinetics
(a Ca
2+ peak was observed after 10 seconds of exposure, Fig. 5B),
potency and efficacy as that of ‘‘free’’ AEA (Fig. 6A). Importantly,
however, the TRPV1-mediated, and, hence, AEA uptake-
dependent, effect of PCL-NP-AEA on [Ca
2+]i was significantly
less sensitive to all the tools used so far to interfere with AEA
cellular uptake or intracellular trafficking. First, it was much less
significantly inhibited by BSA (0.1%) (Fig. 6B), an avid binder of
‘‘free’’ extracellular AEA that strongly inhibits ‘‘free’’ AEA effects
(Fig. 1A) [21]. This finding represents also further evidence that in
Figure 3. Effects of various drugs or combinations thereof
on TRPV1-HEK-293 cell surface topology as observed with
digital holographic (DH) quantitative phase microscopy.
Bars indicate the mean elapsed time (sec) from the addition of
drugs required to observe the first apparent membrane extrusions,
with 1500 s as maximum observed elapsed time. (A)E f f e c to f
anandamide (AEA, 1 mM), per se or with the selective TRPV1
antagonist BCTC (0.1 mM), or in the absence of extracellular Ca
2+
in the medium; of capsaicin (CPS, 0.5 mM) per se or with the
selective TRPV1 antagonist N-(4-Tertiarybutylphenyl)-4-(3-cholor-
phyridin-2-yl)tetrahydropyrazine -1(2H)-carbox-amide (BCTC, 0.1.
mM), or in the absence of extracellular Ca
2+ in the medium; the
calcium ionophore, ionomycin (4 mM), with or without extracellular
Ca
2+ in the medium; and the endoplasmic reticulum Ca
2+-ATPase
inhibitor, thapsigargin (Thaps, 1 mM). The lack of effect up to 1500 s
of AEA and CPS in wild-type (WT) HEK-293 cells is also shown. (B)
Effect of AEA (1 mM), per se or in the presence of the AEA uptake
inhibitor OMDM1 (5 mM), or of fetal bovine serum (10%) in the
medium; of PCL-NP-AEA (1 mM), per se or in the presence of the AEA
uptake inhibitor OMDM1 (5 mM), or of fetal bovine serum (10%) in
the medium; of capsaicin (CPS, 0.5 mM) per se or in the presence of
the AEA uptake inhibitor OMDM1 (5 mM), or of fetal bovine serum
(10%) in the medium. Each bar indicates means 6 sem of 3
independent experiments. In (B) the effect of OMDM1 plus AEA on
mean elapsed time was significantly different (P,0.01) from that of
AEA alone. See also Videos S2 and S4.
doi:10.1371/journal.pone.0010239.g003
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nanoparticles and not free. Next, we found that the effect of PCL-
NP-AEA was less sensitive to plasma membrane cholesterol
depletion and subsequent lipid raft destabilization by MbCD
(Fig. 6B) than ‘‘free’’ AEA (Fig. 1A), although still significantly
inhibited. Indeed, also the NP-endocytotic mechanism was shown
Figure 4. Characterization of anandamide release from PCL-NPs and evidence that PCL-NP rapidly enter HEK-293 cells over-
expressing the human recombinant TRPV1 receptor. (A) Anandamide release from PCL-NP-AEA at 37uC and at a 99.9% dilution in distilled
water (0.5 ml stock suspension in 500 ml water). AEA was measured by HPLC. In a separate experiment, ,80% of AEA was retained by PCL-NP-AEA
incubated for 1 min with the assay buffer used for the experiments of Figs. 1,3. Each bar indicates means 6 sem of at least 3 measurements. (B, C, D)
Representative images of differential interference contrast (DIC) and fluorescence, and merged images, of cells treated for 1 min at 37uC with
Rhodamine-123-loaded nanoparticles (PCL-NP-Rho, 1 mM) (B) or ‘‘free’’ Rhodamine-123 (Rho, 1 mM) (C). Representative images are also shown for
cells treated with ‘‘empty’’ PCL-NP’s (D).
doi:10.1371/journal.pone.0010239.g004
Anandamide in Nanoparticles
PLoS ONE | www.plosone.org 5 April 2010 | Volume 5 | Issue 4 | e10239to rely in part on the formation of lipid rafts [29–31], although
perhaps not as strongly as AEA cellular uptake [32]. The effect of
PCL-NP-AEA was also dramatically less sensitive to oleic acid or
the FABP4 inhibitor [(29-(5-Ethyl-3,4-diphenyl-1H-pyrazol-1-
yl)(1,19-biphenyl)-3-yl)oxy]-acetic acid) (Fig. 6B) than that of
‘‘free’’ AEA (Fig. 1A), thus possibly indicating that NP-mediated
delivery and intracellular release renders AEA less available for the
binding to FABPs. Since this particular inhibitor had never been
tested on AEA uptake [25], we validated its use by showing that it
does inhibit the cellular uptake of [
14C]-AEA in a ‘‘conventional’’
uptake assay carried out in TRPV1- HEK-293 cells (Fig. 7).
Finally, and most importantly, the effect of PCL-NP-AEA on
TRPV1-mediated [Ca
2+]i was much less sensitive to concentra-
tions of the selective AEA uptake inhibitors, OMDM-1 [9] and
AM1172 [22], which instead potently inhibited the effect of ‘‘free’’
AEA (Fig. 6C). Similar results were obtained when the uptake of
PCL-NP-AEA as compared to ‘‘free’’ AEA was studied by using
DH microscopy (Fig. 3B). The TRPV1 and, hence, cellular uptake
dependent effect of PCL-NP-AEA on plasma membrane topology
(induction time 200–300 s), which was still dependent on
extracellular Ca
2+, was not delayed by either BSA or OMDM-1,
unlike what observed with ‘‘free’’ AEA (Fig. 3B, Video S3, Video
S4).
Discussion
The lack, to the present date, of any molecular evidence for an
AEA membrane transporter has generated a heated debate on its
existence, particularly in view of the fact that the lipophilicity of
AEA would allow it to cross the plasma membrane simply by
passive diffusion. Despite indirect data indicating the presence of a
specific and protein-mediated mechanism facilitating AEA trans-
port across the plasma membrane, in a direction according to the
gradient of its concentration, and hence possibly mediating also
AEA release after its de novo biosynthesis, some authors suggested
that such process was uniquely facilitated by the intracellular
enzymatic hydrolysis of this compound by FAAH [15,16]. Later,
other groups showed that AEA cellular uptake can occur rapidly
also in the absence of FAAH [6,17,22], although the actual
mechanism through which this phenomenon occurs, and whether
it is facilitated by membrane or, instead, cytosolic proteins, as
suggested by very recent data [25,26], is yet to be solved. Recent
experiments have also indicated that the temperature-requirement
of AEA cellular uptake is not sufficient evidence for such process to
occur via a ‘‘carrier’’-mediated mechanism, and that temperature-
dependent AEA uptake can occur also in cell ‘‘ghosts’’ or artificial
membranes devoid of membrane proteins [34,35]. Yet, artificial
membranes are not like real cells, and the fact that AEA rapid
diffusion through membranes can occur in the absence of proteins
does not exclude the existence of specific proteins that regulate this
process in real life. To date, the strongest evidence in favor of the
existence of these proteins comes from experiments using synthetic
compounds that are able to interfere with AEA cellular uptake or
release without acting on AEA catabolism or biosynthesis. Some of
these compounds exhibit a pharmacology clearly different from
that of other tools used to inhibit AEA metabolism, such as the
FAAH inhibitors, also in vivo [11]. However, any inhibitor is
selective until proven otherwise, and the fact that these compounds
Figure 5. Representative kinetic experiments for the effects on
[Ca
2+]i in intact HEK-293 cells over-expressing the human
recombinant TRPV1 receptor. Effect of AEA (A) PCL-NP-AEA (B) and
‘‘empty’’ PCL-NP’s (C). The effect of AEA (1 mM) in non-transfected HEK-
293 cells is shown in (D).
doi:10.1371/journal.pone.0010239.g005
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for the existence of a ‘‘transporter’’.
Since all indirect evidence in favor of the presence of an AEA
transporter is debatable, we decided to use, instead, a strategy
aimed at gaining, or failing to gain, direct evidence for its absence.
We studied, in intact HEK-293 cells, which were previously
suggested to possess a putative AEA transporter, but little, if any,
FAAH [20], the pharmacology of the cellular uptake of AEA as
such or prepared in a way to prevent it from interacting with any
plasma membrane protein. The only way to achieve this task was
by incorporating AEA into nanoparticles, a strategy widely used to
deliver drugs directly to intra-cellular targets bypassing their direct
and specific interactions with membrane and intracellular carriers.
We reasoned that if, under these conditions, the uptake of AEA
was still equally sensitive to more or less selective tools previously
shown to inhibit the uptake of ‘‘free’’ AEA, including inhibitors of
the putative AEA transporter, on which the suggestion of the
existence of such mechanism is mostly based, this would represent
compelling evidence against this suggestion. Since different (and,
in some cases, even similar) experimental conditions for the study
of the uptake of radiolabeled AEA by intact cells, including
varying length of incubation of AEA with cells, different types of
plastic ware, etc., were shown to lead to different results, we
decided here to monitor AEA uptake ‘‘while it occurs’’ by using a
biosensor for the entry of AEA into intact cells. This approach
allowed us to avoid all the lengthy processing of, and measure-
ments in, fixated cells, which can be done only much after that the
uptake has occurred. We exploited the property of TRPV1
channels to be activated by AEA exclusively at an intracellular
domain [19] and, subsequently, to cause elevation of [Ca
2+]i,
Figure 6. Effect of specific AEA cellular uptake inhibitors on
PCL-NP-AEA mediated cellular uptake and [Ca
2+]i elevation. (A)
PCL-NP-AEA (&) exhibited similar potency and efficacy as ‘‘free’’ AEA
(%) on [Ca
2+]i in intact HEK-293 cells over-expressing the human
recombinant TRPV1 receptor. The effect is expressed as percent of the
effect on Ca
2+ by ionomycin, 4 mM, and, in both cases, was dose-
dependent and TRPV1-mediated because it was abolished by I-RTX (N
and #). (B) PCL-NP-AEA-induced elevation of [Ca
2+]i in intact TRPV1-
HEK-293 cells over-expressing the human TRPV1 receptor was
significantly less sensitive to pharmacological tools previously used to
specifically interfere with AEA cellular uptake or intracellular trafficking
(BSA, OMDM1, MbC D ,O A ,F A B P 4i n h i b ) .* p ,0.05; ***p,0.001
compared to AEA-PCL-NP + vehicle (n=3–5); #, ##, ### p,0.05,
p,0.01 and p,0.005 compared with AEA+corresponding inhibitor (see
Fig. 1A). (C) PCL-NP-AEA effect (full bars) on TRPV1-mediated [Ca
2+]i was
significantly less sensitive to concentrations of the selective AEA uptake
inhibitors, OMDM-1 and AM1172, which instead strongly affected the
effect of ‘‘free’’ AEA (dotted bars). *p,0.05; ***p,0.001 compared to
the corresponding effect of the inhibitor observed using PCL-NP-AEA; #
p,0.05 compared with PCL-NP-AEA + vehicle. In (B) data are expressed
as percent of the maximal response observed with PCL-NP-AEA
(1 mM) + vehicle (see panel (A)). In (C) data are expressed as percent
of the maximal response observed with either PCL-NP-AEA (1 mM) +
vehicle or AEA (1 mM) + vehicle (see panel (A)). Each bar indicates
means 6 sem of at least 3 independent experiments.
doi:10.1371/journal.pone.0010239.g006
Figure 7. Effect of the fatty acid binding protein-4 (FABP4)
inhibitor [(29-(5-Ethyl-3,4-diphenyl-1H-pyrazol-1-yl)(1,19-bi-
phenyl)-3-yl)oxy]-acetic acid, 50 mM) on the cellular uptake of
[
14C]-anandamide in a ‘‘conventional ‘‘uptake assay carried out
in TRPV1- HEK-293 cells. The amount (cpm) of [
14C]-AEA taken up by
cells at 37uC subtracted of that taken up at 4u after a 90 sec incubation
with the compound is shown on the y axis. Each bar indicates means 6
sem of 3 independent experiments. The effect of the FABP4 inhibitor
was significantly different (P,0.01) from that of vehicle (0.1%
methanol).
doi:10.1371/journal.pone.0010239.g007
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perturbation, measured by DH microscopy (Fig. 8).
We previously used the observation that AEA stimulation of
TRPV1-mediated Ca
2+ elevation in HEK-293 cells is sensitive to
some inhibitors of anandamide uptake to suggest that AEA acts on
TRPV1 at an intracellular domain [20], a suggestion that was later
conclusively demonstrated by using TRPV1 mutants lacking the
intracellular domain between the TM3-TM4 a-helices [19].
However, no previous study has ever validated the measure of
TRPV1-mediated rapid elevation of [Ca
2+]i, or of plasma
membrane perturbation by DH microscopy, as a biosensor for
AEA entry into the cell. Therefore, we first proceeded here to fill
this gap and, indeed, showed that both measurements are capable
to clearly discriminate between the cellular uptake of a fatty acid
amide, such as AEA, for which evidence for interaction with a
putative transporter exists, and another fatty acid amide,
capsaicin, which penetrates the plasma membrane via a
mechanism clearly distinct from that of AEA. We next
demonstrated that the PCL-NPs efficiently and stably incorporate
AEA as well as a fluorescent dye, which they deliver across the
plasma membrane to release it directly into the cytosol. Finally, we
could carry out two major observations: 1) the kinetics, efficacy
and potency of PCL-NP-AEA at activating TRPV1, and hence at
entering HEK-293 cells, are undistinguishable from those of
‘‘free’’ AEA – this allowed a direct comparison between the effects
of inhibitors of AEA uptake on the two types of preparation; 2) the
sensitivity of AEA activation of TRPV1, and hence of AEA
uptake, to previously reported inhibitors of this latter process, and,
in particular, to two selective inhibitors of AEA uptake, was,
instead, significantly different, and dramatically lower when the
endocannabinoid was prevented from interacting with plasma
membrane and intracellular proteins by its incorporation into
PCL-NPs. Instead, the sensitivity of the effects of the two different
AEA formulations to TRPV1 antagonists were identical. These
data fail to demonstrate the hypothesis of the lack of specificity of
the pharmacological tools used here, and in particular of the
inhibitors of anandamide cellular uptake, hypothesis that instead
would have been supported by the observation of identical
sensitivity of PCL-NP-AEA and ‘‘free’’ AEA uptake to these
compounds. Therefore, these data represent strong evidence in
favor of the opposite thesis, i.e. that these inhibitors do indeed act
by preventing the interaction of AEA (but not of PCL-NP-AEA)
with a putative membrane carrier. This approach exemplifies the
widely accepted Euclidean reductio ad absurdum, for which a
proposition that cannot be demonstrated as true proves that its
contrary is instead true, since a third possibility does not exist
(tertium non datur). It is worth mentioning that some selective
inhibitors of AEA uptake, although not those used in the present
study, were previously found to inhibit also AEA interaction with,
and release from, plastic ware [36]. However, this phenomenon is
unlikely to have biased at least our experiments with fluorimetric
detection of intracellular Ca
2+, which were carried out in a quartz
cuvette.
Based on the high loading stability and efficiency of PCL-NP-
AEA and on previous reports about the factors affecting NP cell
uptake [31], it is reasonable to assume that the PCL-NP-AEA
coated by Pluronic F-68 are rapidly internalized by hTRPV1-
HEK-293 cells. Hence, the fact that PCL-NP-AEA effects were
only weakly modified by inhibitors of intracellular AEA trafficking,
which instead efficiently reduced the effects of ‘‘free’’ AEA, is likely
the result of endosomal NP escape and AEA release in close
proximity to its binding site on TRPV1. Therefore, these results
support the innovative idea to carry out the present study with a
validated nanoparticle-based approach. However, there was an
apparent discrepancy in the AEA retention ability of PCL-NPs
upon dilution depending on the method and buffer used to assess
this parameter. The original data of release studies at 99.9%
dilution (0.5 ml stock suspension in 500 ml water) at room
temperature show that ,47% of the AEA initially added remains
associated to NP, whereas the amount was ,80% when a similar
dilution was carried out using the incubation buffer for TRPV1
activity assays. This difference is likely the result of a salting out
effect already reported for THC (solubility in water 2.8 mg/l and
0.77 mg/l in 0.15 M NaCl at 23uC) (it should be noted that THC
solubility in 0.15 M NaCl is close to the reported value for AEA in
0.16 M PBS 7.4) [27]. Thus, the salting out effect might favor the
retention of lipophilic drugs such as AEA by PCL-NPs, and it is
very likely that the release of AEA from PCL-NPs was much
slower following their dilution in the buffers used to carry out
fluorescence and DH microscopy studies than in distilled water.
On the other hand, the fact that ,20% of AEA was potentially
released from PCL-NPs prior to the entry of the latter into cells
probably explains the residual inhibitory effect of BSA and other
pharmacological tools used here on the uptake of PCL-NP-AEA.
In other words, the fact that the uptake inhibitors OMDM1 and
AM1172, or the FABP4 inhibitor, still slightly reduced the
TRPV1-mediated effect of PCL-NP-AEA on Ca
2+, at concentra-
tions which instead inhibited the effect of ‘‘free’’ AEA almost
maximally (note that the maximal inhibition of AEA effect
observed here is about 80%), might be due to the release from
Figure 8. Examples of living cell images, obtained by a digital holographic microscopy (pseudo 3D rendering). (A) In the image, each
pixel grey-value is a measure of the light phase amount in the corresponding point of the sample; (B) codified-colours rendering allows for improved
evaluation of phase values.
doi:10.1371/journal.pone.0010239.g008
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AEA, and to the counteraction by these inhibitors of the uptake of
this small amount of ‘‘free’’ AEA rather than of PCL-NP-AEA.
In conclusion, we have presented here for the first time data
showing that AEA cellular uptake can be studied in living cells
using the TRPV1 channel as a biosensor, DH microscopy as a
means to investigate TRPV1 activity in alternative to fluorescence,
and incorporation of AEA into nanoparticles. Using these novel
technologies we reported that negating the direct interaction of
AEA with putative plasma membrane proteins, by disguising it
into nanoparticles, renders its uptake significantly less sensitive to
most known types of modulators of this process. In our opinion,
these data strongly suggest that AEA uptake is a process that can
be counteracted by selective inhibitors and hence facilitated by
specific plasma membrane protein(s), possibly in concert with
intracellular trafficking proteins. This work should encourage
specific studies aimed at finally identifying and cloning these
proteins. However, our data will have to be challenged in the
future by continuing to study the effect on nanoparticle-
incorporated AEA of yet to be developed tools that specifically
interfere with the cellular uptake of AEA.
Materials and Methods
PCL-NP synthesis and characterization
Poly-e-caprolactone (PCL) was obtained from Sigma (Spain)
and Pluronic F-68 was from Fluka (Germany). All organic HPLC
solvents were from Scharlab (Spain) and water was MilliQ grade
(Millipore, USA). Sigmacote from Sigma was used for glassware
treatment to reduce drug adsorption. Nanoparticles (NP) were
obtained by the nanoprecipitation method from 150 mg poly-
caprolactone and 5 mg anandamide (AEA) (5 mg/ml). Drug
loading was determined by HPLC as previously described [37]
from the amount of drug in the supernatants and the total drug
amount in the sample. Mean particle size and size distribution of
NP was established by laser light diffraction (Microtrac, Leeds and
Northrup, St. Petersburg, USA). Immediate drug release studies
assessed the retention ability of the polymeric carrier upon variable
dilution (from 99.9% to 50%). Drug release behaviour with time
was also studied after incubation of 99% diluted NP samples at
37uC for 1, 4, 8, 14 and 24 h.
Release of AEA from PCL-NP-AEA into the assay medium
by LC-MS
PCL-NP-AEA (1 ml) from the stock solution (1 mM) was diluted
with 1 ml of Tyrode’s solution (145 mM NaCl, 2.5 mM KCl,
1.5 mM CaCl2, 1.2 mM MgCl2, 10 mM D-glucose, and 10 mM
HEPES, pH 7.4), mixed and left at 37uC for 2 min prior to
centrifugation at 15,0006g. After the centrifugation processes,
100 ml of the supernatant were mixed with 10 pmol of d8-AEA (as
an internal standard) and directly analyzed by liquid chromatog-
raphy–atmospheric pressure chemical ionisation-mass spectrome-
try (LC–APCI-MS) [10,28] using a Shimadzu HPLC apparatus
(LC-10ADVP) coupled to a Shimadzu (LCMS- 2010) quadrupole
MS via a Shimadzu APCI interface. The temperature of the APCI
source was 400uC; HPLC column was a Phenomenex (5mm,
150mm64.6mm) reverse phase column, eluted whit a mixture of
Methanol/H2O/CH3COOH 85:15:0.1% (1 ml/min). MS analy-
ses were carried out in the selected ion monitoring in a positive-ion
mode. The selected ions correspond to a mass/charge ratio (m/z)
of 348.0 and 356.0 (respectively [M-H]
+ for deuterated and non-
deuterated AEA). Quantitative measurements of AEA levels were
obtained by analysis of the area ratio between non-deuterated and
deuterated AEA.
Rhodamine-loaded PCL-NP synthesis, characterization
and entry into TRPV1-HEK-293 cells
Rhodamine-loaded NP were also prepared by the nanopreci-
pitation method described above. Rhodamine-123 (Sigma) was
added to the polymer acetone solution before addition of this
mixture to the water-pluronic mixture. The concentration of the
fluorophore was set at 1.0% (w/w) of the polymer as previously
reported [38]. Dye loading (%) was determined by UV-Vis
spectrometry at 505 nm as described for drug loading determina-
tion. Mean particle size and size distribution of NP was established
by laser light diffraction (Microtrac, Leeds and Northrup, St.
Petersburg, USA). Immediate release studies assessed the retention
of the dye by NP upon sequential dilution in PBS (from 50% to
99.9%) in PBS pH 7.4. Rhodamine release with time at 75%
dilution in PBS pH 7.4 was determined at 2, 4, 8 and 24 h.
TRPV1-HEK-293 cells were plated overnight on poly-D-lysine
coated cover slips and, then, incubated for 1 minute at 37uCi na
cell medium containing 1mM of PCL-NP-Rho-123 or ‘‘free’’
Rhodamine-123 or ‘‘empty’’ PCL-NP’s. After incubation, cells
were washed at room temperature in PBS (Phosphate saline
solution, pH=7.4), fixed with paraformaldehyde 4% for 10 min-
utes, washed in PBS and mounted using Aquatex Antifade. The
cells were studied through Leica DMI6000B inverted digital
microscopy. The same cells were observed in bright field by
differential interference contrast (DIC), and in fluorescence field
under appropriate filter for rhodamine-123 excitation. The images
were acquired using digital camera Leica DFC 340FX connected
to the microscope and analyzed by LAS AF 2.2.0
 software.
Intracellular calcium assays
This assay was performed as previously described [20,21].
HEK-293 (human embryonic kidney) cells stably transfected with
the human recombinant TRPV1 were obtained as described
previously [20,21] and grown in minimum essential medium
(EMEM) supplemented with nonessential amino acids, 10% fetal
calf serum, and 2 mM glutamine, maintained under 5% CO2 at
37uC plated on 100-mm diameter Petri dishes. The effect of ‘‘free’’
AEA or PCL-NP-AEA on [Ca
2+]i was determined by using Fluo-
4, a selective intracellular fluorescent probes for Ca
2+. At this aim,
on the day of the experiment, cells were loaded for 1 h at room
temperature with the methyl ester Fluo4-AM 4 mM; containing
0.04% Pluoronic F-127 (Invitrogen) in minimum essential medium
without foetal bovine serum. After loading, cells were washed with
Tyrode’s solution (145 mM NaCl, 2.5 mM KCl, 1.5 mM CaCl2,
1.2 mM MgCl2, 10 mM D-glucose, and 10 mM HEPES, pH 7.4)
and transferred to the quartz cuvette of the spectrofluorimeter
(Perkin-Elmer LS50B; PerkinElmer Life and Analytical Sciences,
Waltham, MA) under continuous stirring. Experiments were
carried out by measuring cell fluorescence at 25uC( lEx=488nm,
lEm=516nm) before and after the addition of compounds. Curve
fitting (sigmoidal dose-response variable slope) and parameter
estimation were performed with GraphPad PrismH (GraphPad
Software Inc., San Diego, CA). The efficacy of the agonists was
first determined by normalizing their effect to the maximum Ca
2+
influx effect on [Ca
2+]i observed with application of 4 mM
ionomycin (Sigma). Potency was expressed as the concentration
of test substances exerting a half-maximal agonist effect (i.e. half-
maximal increases in [Ca
2+]i) (EC50), calculated by using
GraphPadH.
Digital Holographic (DH) quantitative phase microscopy
Digital holography is an optical imaging and measurement
method, utilizing the features of modern digital devices. Holog-
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wavefront scattered from an object, allowing for the formation of
an image of the object itself (‘‘hologram’’). The hologram is
generated by the optical interference between the light coming
from the object and a reference light beam. To record a hologram,
a special optical arrangement is required, using a laser as light
source. In traditional holography, a special photographic plate is
used as recording apparatus. After chemical processing, the
resulting hologram, illuminated with a light beam, act as a
diffraction grating and provides a replication of the original object
wavefront. In DH, the hologram is recorded by a high resolution
digital camera and stored as data-file; the wavefront reconstrution
is carried out by applying numerical methods to the stored data
set. The final output are both an amplitude image and a phase
image of the object. Moreover, a number of suitable algorithms
allow for numerical post-processing (i.e. focus adjustments,
aberrations compensation and more), obtaining enhanced quality
intensity images and very accurate quantitative phase-maps of the
samples. The phase-map is a prominent feature of DH as it
represents, pixel by pixel, the path-lenght measure of the light
trasmitted (or reflected) by the object. DH methods are widely
used for high accuracy measurements and diagnostic applications
in technological and material-science fields, as a non-invasive,
advanced metrological tool, and there is growing interest towards
its biological applications. Fig. 8a shows a tipical, grey-scale, DH
microscope phase-image of living-cells in a Petri dish without any
fixation process. A suitable codified-colours rendering can then
greatly improve the image evaluation (Fig. 8b).
In conventional optical microscopy, well known contrast-
enhancing methods are adopted to overcome the poor visibility of
cells observed by bright-field illumination. Such methods, by
using special optical configurations, are able to convert light-
phase changes into the corrisponding intensity changes, thus
achieving a significant enhancement of sample visibility. Howev-
er, these methods but are not useful for quantitative phase
measurements and suffer of some lateral-resolution reduction. In
this context, DH has been demonstrated to be instead a very
effective, label-free, method for obtaining quantitative phase-
images: on living cell samples it allows an impressive imaging
enhancement and intracellular refractive index and thickness
measurements. Lateral resolution is preserved, while an axial
resolution up to 25 nm in thickness can be obtained. Fast events
can be analyzed by acquiring a sequence of digital holograms,
this being limited only by the frame-rate capability of the used
camera. Presently a few commercial DH microscopes are
available from specialised providers. As references, a few
publications have been selected to take a quick ‘‘bird’s eye’’ look
at the state of the art on biological applications of DH, and as a
useful starting point for further searching. In [39,40,41,42] an
introduction to some implementations of DH microscopy, can be
found: explanations on basic optical configurations and on
numerical data processing methods are provided. The remark-
able (quantitative) imaging capability of DH is demonstrated,
both by single images, of fixed or living cells, and by movies
(available on line). Examples of DH microscopy applications are
reported in the following references: 1) in [43] the DH method
was investigated for detection of lipid-particle dissemination in
living cell cultures, as an alternative procedure to the previous,
time-consuming, methods which need fixing and dying the cells;
2) in [44] an improved implementation of DH demonstrated its
ability in revealing and mapping subcellular motion inside a
tumor spheroid, responding to anticancer drugs; 3) in [45] a DH
method enabled accurate measurements of red blood cells
membrane fluctuations, adopting a procedure to separately
measure the cell refractive index and its thickness. This procedure
is an useful advance towards the solution of an important task of
DH, since it is worthwhile mentioning that the phase measure-
ment achievable by this technique actually represents the path-
lenght variations of the light interacting with the sample. In a
transparent object, such variations are modulated by both
refraction-index and thickness variations of the object itself. In
unpredictable cases, they can be concurrent and, consequently,
added in the final measured phase value. In such a case, it might
become mandatory to decouple their contributes. Studies are
ongoing in defining valid paradigms for specific imaging and/or
quantitative applications of the DH methods in biology: this
requires efforts in comparative studies using a strict interdiscipli-
nar cooperation between experts in life-science and optics.
In the present work, we used an experimental version of a DH
microscope, in transmission configuration, for time-lapse investi-
gations on morphological changes of living-cells, before and after
the addition of compounds. The light source was a 532 nm (green)
laser. Attention was paid to reduce the light intensity impinging on
the cells to minimize thermal or photochemical effects. However
all pilot tests carried out on each measured sample did not show
any evidence of such effects. Cells were placed in small plastic Petri
dishes in EMEM with or without 10% FBS (2 ml) and directly
analysed with the DH microscope, before and after addition of
drugs in DMSO (max volume 2 ml), at room temperature
(24uC62). A large number of measurements were made, each
consisting of two holograms series acquisitions: first, as a control, a
10 minutes sequence of the untreated cells was acquired; then a
sequence was acquired during the addition of compounds. The
frame rate was of 10 frames per second. After the computational
process, the phase-maps collections were used for movies
assembling, in order to analyse the cell topology variations, and
the related timings.
Cellular uptake of radiolabeled AEA by TRPV1-HEK-293
cells
The effect of FABP4 inhibitor [(29-(5-Ethyl-3,4-diphenyl-1H-
pyrazol-1-yl)(1,19-biphenyl)-3-yl)oxy]-acetic acid) on the uptake of
[
14C]-AEA in human embryonic kidney cells over-expressing the
human recombinant TRPV1 protein (TRPV1-HEK-293) was
studied as previously described [6], by using 2 mM (10,000 cpm)
[
14C]-AEA. Cells were plated to 6-wells culture plates at a density
of 1–2610
6 cells/well, preincubated for 30 minutes with 50 mMo f
the FABP4 inhibitor in EMEM at 37uC and subsequently
incubated with [
14C] anandamide for 90 sec. After incubation,
residual [
14C]-AEA in the incubation medium after extraction
with CHCl3/CH3OH 2/1 (by volume), was determined by
scintillation counting of the lyophilized organic phase and used
as a measure of the amount of anandamide taken up by cells.
Specific AEA uptake was determined by subtracting uptake at 4uC
from uptake at 37uC. Data are expressed as cpm of [
14C]-AEA
taken up by cells at 37uC subtracted of that taken up at 4u.
Statistical analyses
All determinations were performed at least in triplicate.
Statistical analysis of the data was performed by analysis of
variance at each point using ANOVA followed by the Bonferroni’s
test.
Supporting Information
Video S1 Effects of anandamide (AEA, 1 microM) on TRPV1-
HEK-293 cell surface topology as observed with digital holo-
graphic (DH) quantitative phase microscopy.
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Video S2 Effects of anandamide (AEA, 1 microM) plus
OMDM-1 (5 microM) on TRPV1-HEK-293 cell surface topology
as observed with digital holographic (DH) quantitative phase
microscopy.
Found at: doi:10.1371/journal.pone.0010239.s002 (1.64 MB
MOV)
Video S3 Effects of PCL-NP-AEA (1 microM) on TRPV1-
HEK-293 cell surface topology as observed with digital holo-
graphic (DH) quantitative phase microscopy.
Found at: doi:10.1371/journal.pone.0010239.s003 (2.33 MB
MOV)
Video S4 Effects of PCL-NP-AEA (1 microM) plus OMDM-1 (5
microM) on TRPV1-HEK-293 cell surface topology as observed
with digital holographic (DH) quantitative phase microscopy.
Found at: doi:10.1371/journal.pone.0010239.s004 (1.21 MB
MOV)
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